Drug news
NICE recommends Keytruda (pembrolizumab) for use in advanced melanoma- Merck Inc.
The National Institute for Health and Care Excellence (NICE) has in draft guidance provisionally recommended the use of Keytruda (pembrolizumab) from Merck Inc. for advanced melanoma which is unresectable or metastatic and where the drug follows treatment by Yervoy (ipilimumab) or a BRAF or MEK inhibitor in BRAF V600 mutation positive disease. The approval is subject to a discount from Merck Inc.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.